SOURCE: National Association of People with AIDS

National Association of People with AIDS

July 13, 2010 13:45 ET

"Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies" to Be Showcased at NAPWA Sponsored Community Treatment Research Forum at XVIII World AIDS Conference

SILVER SPRING, MD--(Marketwire - July 13, 2010) -  The National Association of People with AIDS today announced that it is hosting a Community Treatment Research Forum, "Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies" to be held at the XVIII World AIDS Conference, Vienna, Austria. The event will be held in room Schubert 5, first floor, Thursday, July 22 from 9:45 to 11am.

"NAPWA has a moral responsibility to educate people with HIV and AIDS about immune-based therapy research that one day may lead to a breakthrough for people living with the virus," said Frank Oldham Jr., President and CEO, NAPWA. "The data deserves a collective hearing. We're extremely proud to sponsor this symposium."

Presentations include:

Vacc4x -- a therapeutic HIV-1 vaccine based on modified peptides: Clinical trial results and update on clinical trial development, Per Bengtsson, MD, PhD, CMO and SVP Bionor Immuno

VS411 Safely Reduces Both Excessive Immune System Activation and HIV Viral Load Within 28 Days in Treatment-naïve Individuals: A Phase II HIV AV-HALT Study, Franco Lori, MD, CEO, ViroStatics

Clinical update on AGS-004: Overcoming the challenges to successful HIV immunotherapy, Charles Nicolette, Ph.D., CSO and VP R&D, Argos Therapeutics

Topically Applied DermaVir Safely Boosts HIV-specific Immune Response and Reduces Viral Load Within Six Months in Treatment-naïve Individuals: A Phase II HIV Therapeutic Vaccine Study, Julianna Lisziewicz, PhD, CEO, Genetic Immunity

TBR-652, a potent dual chemokine receptor 5/chemokine receptor 2 (CCR5/CCR2) antagonist in phase 2 development for treatment of HIV infection, Richard Ogden PhD, Scientific Development Advisor, Tobira Therapeutics

Advanced Development of Dual Acting Pyrimidinediones (IQP-0410 and IQP-0528) as Highly Potent Anti-HIV Therapeutic Drugs and Topical Microbicides, Robert Buckheit, Ph.D., President and Chief Scientific Officer, ImQuest Life Sciences, Inc.

Founded in 1983 as the first network of people living with HIV/AIDS (PLWHA), the National Association of People with AIDS (NAPWA) is the oldest national AIDS organization. NAPWA is the trusted independent voice for all people living with HIV/AIDS in the United States. By engaging in the aforementioned activities, NAPWA remains a strong voice in policy, capacity building, leadership development, and social networking. NAPWA is a 501(c) 3 non-profit organization based in Silver Spring, Maryland. For more information about NAPWA, please visit www.napwa.org.

Contact Information

  • CONTACTS:
    Peter Kronenberg
    240 247-1025

    David Sheon
    In Vienna for NAPWA
    +1 202 422-6999